Published in Mol Ther Methods Clin Dev on January 25, 2017
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med (2006) 13.51
Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med (2011) 11.01
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol (2008) 6.82
Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol (2010) 4.62
Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis (2009) 4.27
Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther (2010) 3.37
Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther (2009) 3.33
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med (2015) 3.18
Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther (2011) 3.10
Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. Blood (2005) 2.29
How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol (2006) 2.14
Metabolic pathways in T cell fate and function. Trends Immunol (2012) 1.97
Innate and adaptive immune activation in the brain of MPS IIIB mouse model. J Neurosci Res (2009) 1.90
Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant (2010) 1.86
Glucocorticosteroids: current and future directions. Br J Pharmacol (2011) 1.85
Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery. Mol Ther (2011) 1.79
Mouse model of Sanfilippo syndrome type B produced by targeted disruption of the gene encoding alpha-N-acetylglucosaminidase. Proc Natl Acad Sci U S A (1999) 1.79
Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors. Hum Gene Ther (2011) 1.71
Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci Transl Med (2013) 1.56
Rapamycin: an anti-cancer immunosuppressant? Crit Rev Oncol Hematol (2005) 1.50
A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. Mol Ther (2011) 1.29
PEG conjugation moderately protects adeno-associated viral vectors against antibody neutralization. Biotechnol Bioeng (2005) 1.20
Correction of pathological accumulation of glycosaminoglycans in central nervous system and peripheral tissues of MPSIIIA mice through systemic AAV9 gene transfer. Hum Gene Ther (2012) 1.14
Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B. Mol Ther (2012) 1.13
The establishment of the plasma cell survival niche in the bone marrow. Immunol Rev (2013) 1.09
Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery. Mol Ther (2013) 1.06
Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine. Gene Ther (2011) 1.05
Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum Gene Ther Methods (2013) 1.02
A preclinical animal model to assess the effect of pre-existing immunity on AAV-mediated gene transfer. Mol Ther (2009) 1.00
Optimization of stealth adeno-associated virus vectors by randomization of immunogenic epitopes. Virology (2009) 0.96
Vascular delivery of rAAVrh74.MCK.GALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin α2 surrogates. Mol Ther (2013) 0.94
Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primates. Hum Gene Ther Clin Dev (2014) 0.91
Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates. J Transl Med (2012) 0.89
B-Cell Depletion is Protective Against Anti-AAV Capsid Immune Response: A Human Subject Case Study. Mol Ther Methods Clin Dev (2014) 0.88
Differentiation and maintenance of long-lived plasma cells. Curr Opin Immunol (2015) 0.84
Rictor is required for early B cell development in bone marrow. PLoS One (2014) 0.84
AAV does the shuffle. Nat Biotechnol (2006) 0.83
Serology in the 21st century: the molecular-level analysis of the serum antibody repertoire. Curr Opin Immunol (2015) 0.82
Determination of anti-adeno-associated virus vector neutralizing antibody titer with an in vitro reporter system. Hum Gene Ther Methods (2015) 0.81
Prediction of adeno-associated virus neutralizing antibody activity for clinical application. Gene Ther (2015) 0.81
Human T follicular helper cells: development and subsets. Adv Exp Med Biol (2013) 0.81
The activation of the adaptive immune system: cross-talk between antigen-presenting cells, T cells and B cells. Immunol Lett (2014) 0.80
Influence of corticosteroid therapy on the serum antibody response to influenza vaccine in elderly patients with chronic pulmonary diseases. EXCLI J (2013) 0.77
Conditional Disruption of Raptor Reveals an Essential Role for mTORC1 in B Cell Development, Survival, and Metabolism. J Immunol (2016) 0.77